Teriparatide - Rare Disease Therapeutics

Drug Profile

Teriparatide - Rare Disease Therapeutics

Alternative Names: hPTH (1-34) - Rare Disease Therapeutics; Parathyroid hormone (1-34) - Rare Disease Therapeutics; Parathyroid-hormone-1-34; PTH-1-84

Latest Information Update: 16 Jun 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rare Disease Therapeutics
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypoparathyroidism

Most Recent Events

  • 21 Oct 2013 Biomarkers information updated
  • 16 Jun 2005 Discontinued - Phase-III for Hypoparathyroidism in USA (unspecified route)
  • 25 Jun 2001 Phase-III clinical trials for Hypoparathyroidism in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top